Cobicistat (trade name: Tybost) been approved in Germany since September 2013 for the treatment of HIV-1 infection in adults. As of March 2020 it is also an option for the treatment of HIV-1 infection in teenagers aged 12 and over.

The human immunodeficiency virus (HIV) multiplies in cells of the immune system and destroys them. Without proper treatment, the immune system of most HIV patients is weakened so much over time that they become seriously ill. This stage is called “AIDS” (acquired immunodeficiency syndrome).

Although the currently available medications can't cure HIV, they can prevent immunodeficiency for many years. But in some people the medication may become ineffective over time, allowing the viruses to multiply more again.

Cobicistat is a booster: It is combined with atazanavir or darunavir in order to enhance their effect.


Cobicistat is taken once a day in tablet form with a meal. Each tablets contains 150 mg cobicistat.

Other treatments

Teenagers with HIV infections who have treatment with atazanavir or darunavir are typically given ritonavir as a booster.


In 2020, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) wanted to look into into the advantages and disadvantages of cobicistat when used as a booster of atazanavir or darunavir in the treatment of HIV-1 infections in teenagers compared to the standard treatments.

But the manufacturer didn’t provide any suitable data with which to do the assessment.

More information

This information summarizes the main results of a review by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The IQWiG review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the review and the hearings received, the G-BA passed a resolution on the added benefit of cobicistat (Tybost).